同种异体围产期组织在肌肉骨骼再生医学中的应用：系统评价方案。
Allogenic perinatal tissue for musculoskeletal regenerative medicine applications: a systematic review protocol.
机构信息
The Royal College of Surgeons in Ireland, Dublin, Ireland.
Department of Musculoskeletal Disorders, School of Medicine and Surgery, University of Salerno, 84084, Fisciano, Italy.
出版信息
J Orthop Surg Res. 2022 Jun 11;17(1):307. doi: 10.1186/s13018-022-03197-z.
BACKGROUND
Musculoskeletal ailments impact the lives of millions of people, and at times necessitate surgery followed by physiotherapy, drug treatments, or immobilization. Regenerative musculoskeletal medicine has undergone enormous progress over the last few decades. Sources of tissues used for regenerative medicine purposes can be grouped into autologous or allogenic. Although autologous sources are promising, there is a wide range of limitations with the treatment, including the lack of randomized controlled studies for orthopaedic conditions, donor site morbidity, and highly variable outcomes for patients. Allogenic sources bypass some of these shortcomings and are a promising source for orthopaedic regenerative medicine applications.
METHODS
A systematic search will be performed using PubMed, Elsevier, ScienceDirect, and Google Scholar databases for articles published in English before May 2022. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and guidelines will be used. Studies will be eligible if they apply to acute and chronic orthopaedic musculoskeletal complications or animal or human disease models. Publications must include the use of MSCs and/or tissue obtained from amniotic/chorionic membrane, amniotic fluid, umbilical cord, and/or umbilical cord-derived Wharton's jelly as an intervention. Placebos, noninjury models, acute injury models, non-injury models, and gold standard treatments will be compared. The study selection will be performed by two independent reviewers using a dedicated reference management software. Data synthesis and meta-analysis will be performed separately for preclinical and clinical studies.
DISCUSSION
The results will be published in relevant peer-reviewed scientific journals. Investigators will present results at national or international conferences.
TRIAL REGISTRATION
The Protocol will be registered on PROSPERO international prospective register of systematic reviews prior to commencement.
背景
肌肉骨骼疾病影响着数百万人的生活，有时需要手术，随后进行物理治疗、药物治疗或固定。在过去几十年中，再生肌肉骨骼医学取得了巨大进展。用于再生医学目的的组织来源可分为自体或同种异体。虽然自体来源很有前景，但该治疗方法存在广泛的局限性，包括缺乏针对骨科疾病的随机对照研究、供体部位发病率以及患者结果差异很大。同种异体来源可以避免这些缺点，是骨科再生医学应用的有前途的来源。
方法
将使用 PubMed、Elsevier、ScienceDirect 和 Google Scholar 数据库对 2022 年 5 月之前发表的英文文章进行系统检索。将使用系统评价和荟萃分析的首选报告项目和指南。如果研究适用于急性和慢性骨科肌肉骨骼并发症或动物或人类疾病模型，则符合入选标准。出版物必须包括使用间充质干细胞和/或取自羊膜/绒毛膜、羊水、脐带和/或脐带衍生的华通氏胶的组织作为干预措施。将比较安慰剂、非损伤模型、急性损伤模型、非损伤模型和金标准治疗。研究选择将由两名独立评审员使用专用参考管理软件进行。将分别对临床前研究和临床研究进行数据综合和荟萃分析。
讨论
结果将发表在相关的同行评议科学期刊上。研究人员将在国家或国际会议上报告结果。
试验注册
在开始前，该方案将在 PROSPERO 国际系统评价前瞻性注册库中进行注册。
Zotero 插件